October 24, interim report
July – September 2024
Alligator hosted a webinar on Thursday, October 24, at 3 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the Q3 interim report, which was followed by a Q&A session.
The call was held in English, and can be requested below.
LATEST NEWS
Alligator Bioscience publishes financial calendar for 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General …
Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
Lund, Sweden, November 27, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that th …
Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shar …